Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8.5
USERS' SCORE
Good
Based on 10 Reviews
8.5
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
Calcium (from Calcium-Magnesium Inositol Hexaphosphate)
100 mg
8%
Inositol Hexaphosphate (from Calcium-Magnesium Inositol Hexaphosphate)
500 mg
â€
Top Medical Research Studies
9
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Read More
8
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
Read More
Most Useful Reviews
10
Optimal anti-cancer use
18 people found this helpful
Number 1 anti-cancer supplement! Just make sure to take it with distilled or reverse osmosis water and at least 3 hours away from any food. It’s easiest to take first thing in the morning and then wait to eat for three hours.
Read More
9
Effective anti-cancer supplement
5 people found this helpful
IP6 is a great anti-cancer supplement!
Read More
9
Supportive therapy
This, alongside Turkey Tail Mushroom, vitamin C, soursop, and others, has aided my mother in her fight against breast cancer. Research these products; you'll be pleased with the findings!
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 2 Researches
8.5
- All Researches
9
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Read More
8
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
Read More
User Reviews
USERS' SCORE
Good
Based on 10 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
10
Optimal anti-cancer use
18 people found this helpful
Number 1 anti-cancer supplement! Just make sure to take it with distilled or reverse osmosis water and at least 3 hours away from any food. It’s easiest to take first thing in the morning and then wait to eat for three hours.
Read More
9
Effective anti-cancer supplement
5 people found this helpful
IP6 is a great anti-cancer supplement!
Read More
9
Supportive therapy
This, alongside Turkey Tail Mushroom, vitamin C, soursop, and others, has aided my mother in her fight against breast cancer. Research these products; you'll be pleased with the findings!
Read More
7.5
Breast cancer protocol
12 people found this helpful
Essential! I include this in my protocol for managing breast cancer and intend to continue using it for an extended period.
Read More
9
Post-cancer surgery use
7 people found this helpful
I have been using IP6 for four years following a cancer operation. The prognosis was grim, but a friend recommended it, and I’m currently cancer-free. Whether it's due to this supplement or not, I plan to continue taking it as a precaution.
Read More
Frequently Asked Questions
9
Post-cancer surgery use
7 people found this helpful
I have been using IP6 for four years following a cancer operation. The prognosis was grim, but a friend recommended it, and I’m currently cancer-free. Whether it's due to this supplement or not, I plan to continue taking it as a precaution.
7.5
Effective for prevention
4 people found this helpful
Awesome product! I noticed its beneficial effects immediately. While I primarily use it as a cancer preventative, it also helped alleviate a rash I was experiencing.
7.5
Breast cancer protocol
12 people found this helpful
Essential! I include this in my protocol for managing breast cancer and intend to continue using it for an extended period.
9
Supportive therapy
This, alongside Turkey Tail Mushroom, vitamin C, soursop, and others, has aided my mother in her fight against breast cancer. Research these products; you'll be pleased with the findings!
9
We explored the role of the sodium/myo-inositol co-transporter SLC5A3 in non-small cell lung cancer (NSCLC). Our research aimed to uncover how inositol impacts cancer cell growth and survival.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
Through our analysis, we discovered that SLC5A3 levels were significantly higher in NSCLC tissues than in normal lung tissues. When we reduced SLC5A3 using specific techniques, we observed a notable decrease in cell growth, migration, and an increase in cell death. This suggests that SLC5A3 plays a pivotal role in maintaining cancer cell viability.
Furthermore, we found that adding myo-inositol or activating a related protein pathway helped reverse the effects seen with SLC5A3 depletion. In animal models, we noted that directly targeting SLC5A3 reduced tumor growth significantly, reinforcing the idea that it is a critical factor in NSCLC progression.
Overall, our findings highlight that SLC5A3 promotes cancer cell growth potentially by enhancing myo-inositol levels and activating specific signaling pathways. This offers new insights into potential treatment strategies targeting SLC5A3 for lung cancer patients.
8
In our exploration of lung cancer treatments, we investigated how myo-inositol (MI) works alongside other agents to combat lung tumors. We treated A/J mice with a tobacco smoke carcinogen and followed up with various combinations of MI, iloprost (IL), and rapamycin for 17 weeks. Our analysis focused on the number and size of induced lung tumors.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
The results were promising! We found that MI alone, along with its combinations with IL and rapamycin, significantly decreased the number of lung tumors. Particularly, the combination of MI with IL or rapamycin prevented the development of larger tumors, showing a strong 79% and 67% reduction in tumor multiplicity, respectively.
One striking finding of our study was the effects on immune response. Those treated with MI plus IL or rapamycin experienced increased infiltration of key immune cells into the tumors and a reduction in the expression of an immune checkpoint protein known as PD-L1. All treatment groups, aside from those receiving IL alone, also showed greater rates of cell death and reduced cell proliferation.
Through this research, we observed that combining IL or rapamycin with MI improved its effectiveness in preventing lung tumor formation and growth more than MI alone. This suggests that these combinations could be beneficial in lung cancer chemoprevention strategies.
References
- Cui Z, Mu C, Wu Z, Pan S, Cheng Z, et al. The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth. Cell Death Dis. 2022;13:569. doi:10.1038/s41419-022-05017-y
- Kassie F, Bagherpoor AJ, Kovacs K, Seelig D. Combinatory lung tumor inhibition by myo-inositol and iloprost/rapamycin: association with immunomodulation. Carcinogenesis. 2022;43:547. doi:10.1093/carcin/bgac019
